Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $137,700.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $22.95, for a total transaction of $137,700.00. Following the completion of the transaction, the insider directly owned 59,992 shares of the company’s stock, valued at $1,376,816.40. The trade was a 9.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 30th, Filip Janku sold 5,407 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50.
• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.22, for a total transaction of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ GLUE opened at $24.21 on Friday. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77. The business’s 50 day moving average is $19.30 and its two-hundred day moving average is $18.84. The stock has a market capitalization of $2.05 billion, a P/E ratio of -16.36 and a beta of 1.56.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Wells Fargo & Company reduced their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Guggenheim lifted their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.33.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of large investors have recently bought and sold shares of GLUE. Price T Rowe Associates Inc. MD grew its position in Monte Rosa Therapeutics by 10.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after acquiring an additional 481,844 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after purchasing an additional 257,547 shares during the last quarter. State Street Corp boosted its stake in shares of Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after purchasing an additional 1,260,707 shares during the period. AQR Capital Management LLC boosted its stake in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after purchasing an additional 1,054,406 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Monte Rosa Therapeutics by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after purchasing an additional 53,278 shares during the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.